Business Wire (Fri, 28-Aug 6:40 PM ET)
Takeda gains approval of rusfertide for polycythemia vera
Seeking Alpha News (Fri, 28-Aug 5:44 PM ET)
Novavax announces regulatory approvals for updated COVID shot
Seeking Alpha News (Fri, 28-Aug 9:25 AM ET)
Business Wire (Mon, 24-Aug 2:36 AM ET)
Takeda’s FDA Approval for ORZEYFUL Sets a New Standard in Narcolepsy Type 1 Care
Market Chameleon (Thu, 6-Aug 5:13 AM ET)
Business Wire (Wed, 5-Aug 6:10 PM ET)
Business Wire (Thu, 30-Jul 2:37 AM ET)
Business Wire (Thu, 16-Jul 6:00 PM ET)
Business Wire (Sun, 12-Jul 7:00 PM ET)
Business Wire (Wed, 24-Jun 3:05 AM ET)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) trades on the NYSE stock market under the symbol TAK.
As of September 2, 2026, TAK stock price climbed to $18.43 with 1,651,561 million shares trading.
TAK has a beta of 0.15, meaning it tends to be less sensitive to market movements. TAK has a correlation of 0.01 to the broad based SPY ETF.
TAK has a market cap of $58.86 billion. This is considered a Large Cap stock.
Last quarter Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) reported $8 billion in Revenue and $.48 earnings per share. This beat revenue expectation by $595 million and exceeded earnings estimates by $.09.
In the last 3 years, TAK traded as high as $18.90 and as low as $12.58.
The top ETF exchange traded funds that TAK belongs to (by Net Assets): FVD, PPH, AVDE, APIE, VEU.
TAK has outperformed the market in the last year with a price return of +22.9% while the SPY ETF gained +19.8%. TAK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.3% and +2.1%, respectively, while the SPY returned +1.1% and -0.3%, respectively.
TAK support price is $17.98 and resistance is $18.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAK shares will trade within this expected range on the day.